THROMBOSIS RESEARCH INSTITUTE
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1989-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://tri-london.ac.uk
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Thrombosis Research Institute
- Target Recruit Count
- 219
- Registration Number
- NCT04492254
- Locations
- 🇦🇺
Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital, Melbourne, Australia
🇧🇪Dr Frank Cools, National Co-ordinating Investigator, AZ Klina, Brasschaat, Belgium
🇿🇦Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand, Johannesburg, South Africa
Rivaroxaban Evaluation in Real Life Settings
- Conditions
- StrokeAtrial Fibrillation
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Thrombosis Research Institute
- Target Recruit Count
- 5278
- Registration Number
- NCT02444221
- Locations
- 🇫🇷
Prof. Jean-Yues LeHeuzey, National Coordinating Investigator, Hopital Europeen Georges Pompidou, Paris, France
🇬🇧Thrombosis Research Institute, London, United Kingdom
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events
- Conditions
- Venous ThromboembolismDeep Vein ThrombosisPulmonary Embolism
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Thrombosis Research Institute
- Target Recruit Count
- 10679
- Registration Number
- NCT02155491
- Locations
- 🇺🇸
Dr Terence Hart, Muscle Shoals, Alabama, United States
Global Anticoagulant Registry in the Field
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2010-03-19
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Thrombosis Research Institute
- Target Recruit Count
- 57250
- Registration Number
- NCT01090362
- Locations
- 🇺🇸
Prof. Samuel Goldhaber, Boston, Massachusetts, United States
🇦🇷Dr Hector Luciardi, National Co-ordinating Investigator, National University of Tucuman, Tucumán, Argentina
🇦🇺Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital, Melbourne, Australia
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
- Conditions
- Gastroesophageal CancerGastric Cancer
- Interventions
- Drug: Standard Chemotherapy
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Thrombosis Research Institute
- Target Recruit Count
- 740
- Registration Number
- NCT00718354
- Locations
- 🇮🇳
Mahatma Gandhi Cancer Hospital & Research Institute ,1/7 M.V.P. Colony, - ,, ., Vishakhapattanam, Andhra Pradesh, India
🇮🇳Mahavir Cancer Sansthan,Phulwari Sharif, Patna, Bihar, India
🇮🇳Gujarat Cancer Research Institute, Civil Hospital Campus,Asarwa, ,, Ahmedabad, Gujarat,, India